Trial Profile
A Randomized, Placebo-controlled Trial of Pre-treatment HPV Vaccination on Outcomes to LEEP Treatment of Cervical High Grade Squamous Intraepithelial Lesions in HIV-infected Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 11 Jun 2020 Status changed from recruiting to completed.
- 12 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.
- 12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.